In the trials it was rare: in the Wegovy weight trials it was confirmed in 4 people on the drug and 1 on placebo, and in the Zepbound weight trials in 0.2% of each group.1,2,3
What it is
NIDDK describes two forms. Acute pancreatitis starts suddenly and is short-term; most people get better within several days with treatment, though some have a severe form that needs a long hospital stay. Chronic pancreatitis lasts and gets worse over time, which can damage the pancreas for good. Both are serious.1 In the United States there are about 275,000 hospital stays for acute pancreatitis each year. Complications can include blocked bile or pancreatic ducts, fluid-filled pseudocysts, lasting damage to the pancreas, failure of the heart, lungs or kidneys, and death.1
The most common causes are gallstones and heavy alcohol use, followed by genetic disorders of the pancreas and some medicines. Diabetes, high triglycerides, obesity and smoking all raise the risk, as does a personal or family history of gallstones or of pancreatitis, and men are more likely to get it than women.1,4 Several of those risk factors are common in the people GLP-1 medicines are prescribed for, which is part of why the question is hard to study.
Warning signs
The main symptom of acute pancreatitis is pain in the upper abdomen that may spread to the back. It may start slowly or suddenly, be mild or severe, and last several days. Fever, nausea and vomiting, a fast heartbeat and a swollen or tender abdomen can come with it, and people usually look and feel seriously ill. NIDDK advises seeking care right away for abdominal pain that is severe or getting worse, especially with nausea, vomiting or fever.4
The Wegovy label asks that people starting the medicine be watched for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, the drug is stopped.2 Our page on stomach pain on a GLP-1 sets out which pain is ordinary and which needs a doctor the same day.
What the trials found
- Wegovy weight trials: confirmed in 4 people on Wegovy, 0.2 cases per 100 patient-years, and 1 on placebo, under 0.1.
- Zepbound weight trials: 0.2% in both groups, 0.14 against 0.15 cases per 100 patient-years.
- Tirzepatide in diabetes trials: 14 events in 13 people on tirzepatide against 3 on comparators, 0.23 against 0.11 per 100 years.
- Heart trials: in LEADER, pancreatitis was slightly less common on liraglutide; in Harmony Outcomes it occurred in 10 people on albiglutide and 7 on placebo; in ELIXA it was not more common on lixisenatide.
WEGOVY and ZEPBOUND labels; trial reports.2,3,5,6,7
These numbers are small, and no single trial is large enough to settle whether GLP-1 medicines raise the risk. The labels keep the warning because cases, including fatal hemorrhagic or necrotizing pancreatitis, have been observed in people taking them.2
Alcohol and gallstones
Two of the main causes of pancreatitis overlap with life on a GLP-1 medicine. Heavy drinking is a leading cause, and gallstones are another; the Wegovy label notes that the medicine is associated with more gallstones and gallbladder inflammation.1,2 The practical steps follow from the labels and NIDDK: keep drinking moderate, and report new or severe upper abdominal pain without waiting. Our page on alcohol on a GLP-1 covers drinking.
Sources
- National Institute of Diabetes and Digestive and Kidney Diseases. Definition and facts for pancreatitis. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 5.2, 5.3 and 6.1. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov
- National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and causes of pancreatitis. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
- Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes (Harmony Outcomes). Lancet 2018;392:1519-1529. doi:10.1016/S0140-6736(18)32261-X
- Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med 2015;373:2247-2257. doi:10.1056/NEJMoa1509225
Related analyses
Stomach pain on a GLP-1: what is common, what is not, and when to worry
Alcohol on a GLP-1: what the labels say, what counts as a drink, and what five studies found
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic side effects: how common each one is by dose, and when they ease
Log any new or severe belly pain with your doses, so you can show your doctor the timeline.
Open Dose Insider